Provided by Tiger Trade Technology Pte. Ltd.

Addex Therapeutics Ltd

7.00
+0.17002.49%
Volume:845.00
Turnover:5.84K
Market Cap:8.86M
PE:-0.77
High:7.00
Open:6.81
Low:6.81
Close:6.83
52wk High:12.05
52wk Low:5.41
Shares:1.27M
Float Shares:1.07M
Volume Ratio:0.40
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.1500
EPS(LYR):-8.9287
ROE:-87.53%
ROA:-15.90%
PB:1.17
PE(LYR):-0.78

Loading ...

Company Profile

Company Name:
Addex Therapeutics Ltd
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
2
Office Location:
Chemin des Mines, 9,Geneva,Geneva,Switzerland
Zip Code:
1202
Fax:
41 22 884 1556
Introduction:
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Directors

Name
Position
Tim Dyer
Chief Executive Officer and Director
Vincent Lawton
Chairman of the Board
Isaac Manke
Independent Director
Jake Nunn
Independent Director
Raymond Hill
Independent Director
Roger Mills
Chief Medical Officer and Director

Shareholders

Name
Position
Tim Dyer
Chief Executive Officer and Director
Lénaic Teyssédou
Head of Finance
Mikhail Kalinichev
Head of Translational Science
Roger Mills
Chief Medical Officer and Director